<DOC>
	<DOCNO>NCT00612495</DOCNO>
	<brief_summary>To determine efficacy ( response rate [ RR ] , time progression survival ) oxaliplatin single agent oxaliplatin combination 5 FU patient advanced/metastatic endometrial cancer pretreated one prior chemotherapy regimen contain cisplatin ( CDDP ) carboplatin define safety profile arm mention regimen patient</brief_summary>
	<brief_title>Endometrial Cancer - LOHP Alone With 5FU</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients age least 18 year , locally advanced , recurrent metastatic endometrial adenocarcinoma , histologically diagnose ; least 1 bidimensionally measurable lesion ( &gt; =to 2 cm compute tomography [ CT ] /magnetic resonance image [ MRI ] &gt; =to 1 cm clinical lymph node confirm ultrasound &gt; =to 1 cm skin lesion confirm photograph ruler ) locate nonirradiated area measure less 2 week inclusion , accord National Cancer Institute Common Toxicity Criteria ( NCICTC ) . Patients previously treat locally advanced/metastatic disease chemoradiotherapy ( total CDDP dose &gt; =to 100 mg/m2 ) chemotherapy contain CDDP carboplatin least 4 week ' washout period discontinuation prior chemotherapy fully recover toxic effect prior chemotherapy ( except symptomatic peripheral neuropathy &lt; =to NCICTC grade 1 alopecia ) . Patients clinically radiologically document PD recurrence last chemotherapy hormone therapy ( hormone therapy stop study entry ) , Eastern Cooperative Oncology Group performance status ( ECOG PS ) &lt; =to 2 , life expectancy &gt; =to 3 month , adequate bone marrow reserve , normal renal liver function ( neutrophil count &gt; =to 2000/mm³ ; platelet count &gt; =to 100 000/mm³ ; creatinine level &lt; =to 1.5 x upper limit normal [ ULN ] institutional value creatinine clearance &gt; 60 mL/min ; total bilirubin level &lt; 1.5 x ULN ; [ alanine amino transferase/aspartate aminotransferase &lt; 2.5 x ULN without liver metastasis , &lt; 5 x ULN liver metastasis ] ) . Laboratory value obtain week precede study entry . Signed informed consent ( prior study procedure )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>